Pharming Group N.V.
PHAR$1.27B
Small CapNASDAQBiotechnology🇺🇸North America404 employees
Drugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Jul 9, 2026
10wMarket Overview
Stock performance and key metrics
PHAR News
Catalyst Timeline
3 upcoming, 1 past
Drug Pipeline
Leniolisib
PIDs Linked to PI3K
i.v. recombinant human C1 inhibitor
Genetic Disorders
recombinant human C1 inhibitor
Hereditary Angioedema
rhC1INH
Hereditary Angioedema
Ruconest
Confirmed Coronavirus Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Leniolisib | Phase 3 | PIDs Linked to PI3K | - | - |
i.v. recombinant human C1 inhibitor | Phase 3 | Genetic Disorders | - | - |
recombinant human C1 inhibitor | Phase 3 | Hereditary Angioedema | - | - |
rhC1INH | Phase 3 | Hereditary Angioedema | - | - |
Ruconest | Phase 2 | Confirmed Coronavirus Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply